Why the study?
Does very high power, short duration (vHPSD) ablation demonstrate clinical feasibility and safety in patients with paroxysmal atrial fibrillation?
Does very high power, short duration (vHPSD) ablation demonstrate clinical feasibility and safety in patients with paroxysmal atrial fibrillation?
Answers are grounded in this paper and cite their sources.
First-in-human evidence shows that very high power, short duration ablation with a novel temperature-controlled catheter is feasible and safe for paroxysmal AF, potentially reducing procedure times.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: